ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies - PARP Inhibitors

ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies - PARP Inhibitors is organized by i3 Health and will be held from Dec 07, 2022 - Dec 06, 2023.,,Statement Of Need:,Breast cancer is the most commonly diagnosed cancer in women. A BRCA1 or BRCA2 mutation is found in approximately 5% of patients with breast cancer and is detected in 30% of patients who have a family history of breast or ovarian cancer (ACS, 2019). In patients with human epidermal growth factor receptor 2 (HER2)–negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, inhibition of poly–(ADP-ribose) polymerase (PARP) is highly efficacious, even in early breast cancer. PARP inhibitors block pathways involved in DNA single-stranded break repair. In combination with a germline or somatic mutation impacting the homologous recombination DNA repair genes BRCA1 or BRCA2, PARP inhibition leads to stalled replication, DNA damage, and cancer cell death (Cortesi et al, 2021). In this session, Janie Metsker, RN, BSN, CN-BN, will explain the benefit of PARP inhibitors for breast cancer in patients with germline BRCA mutations and will present the latest data justifying the recent approval of olaparib for adjuvant therapy in high-risk early breast cancer (Tutt et al, 2021). She will also highlight the side effect profiles of PARP inhibitors and the importance of counseling patients about the side effects they may experience.,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Assess the indications and safety and efficacy profiles of novel PARP inhibitors for breast cancer,• Evaluate clinical tools for assessing and grading adverse events associated with novel PARP inhibitors,• Apply strategies to optimize the safety and tolerability of novel PARP inhibitors,• Develop educational strategies to help patients understand the benefits and risks of their breast cancer treatment plan,,In this session, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at Saint Luke’s Hospital, Kansas City, Missouri, will explain the benefit of PARP inhibitors for breast cancer in patients with germline BRCA mutations and will present the latest data justifying the recent approval of olaparib for adjuvant therapy in high-risk early breast cancer. She will also highlight the side effect profiles of PARP inhibitors and the importance of counseling patients about the side effects they may experience. Start the activity now!